Karyopharm Therapeutics Inc. ã¯ãæ°ããããæ²»çæ³ã®å
é§è
ã§ããåæ¥æ®µéã®è£œè¬äŒç€Ÿã§ãããããã®ä»ã®çŸæ£ã®æ²»çã®ããã«æ žèŒžåºãæšçãšããè¬å€ãçºèŠãéçºãåååããŠããŸããå瀟ã®éžæçæ žèŒžåºé»å®³å€ (SINE) ååç©ã¯ãæ žèŒžåºã¿ã³ãã¯è³ª XPO1 ã«çµåããŠé»å®³ããããšã«ãã£ãŠæ©èœããŸããå瀟ã®äž»åååç©ã§ãã XPOVIO (selinexor) ã¯ãå°ãªããšã 1 åã®æ²»çåŸã®å€çºæ§éªšé«è
«ã®æäººæ£è
ã®æ²»çã«ããã Velcade (ãã«ããŸãã) ããã³ãããµã¡ã¿ãŸã³ãšã®äœµçšãå€çºæ§éªšé«è
«ã®æäººæ£è
ã®æ²»çã«ããããããµã¡ã¿ãŸã³ãšã®äœµçšãããã³åçºæ§ãŸãã¯é£æ²»æ§ã®ã³ãŸãæ§å€§çްèå B 现èãªã³ãè
«ã®æäººæ£è
ã®æ²»çã«ãããåç¬çæ³ãšããŠãªã©ãç±³åœã§ããŸããŸãªè¡æ¶²æªæ§è
«çã®é©å¿çã§æ¿èªãããŠããŸããå瀟㮠NEXPOVIO (ã»ãªãã¯ãœã«) ã¯ã欧å·å§å¡äŒã«ãããå€çºæ§éªšé«è
«ã®é節ãªåæ²»çæŽãæã€æäººæ£è
ã«å¯Ÿãããããµã¡ã¿ãŸã³ãšã®äœµçšã§æ¡ä»¶ä»ã販売æ¿èªãååŸããŠããŸããããã«ãå瀟㮠SINE ååç©ã¯ãç¥çµå€æ§ãççãèªå·±å
ç«çŸæ£ãç¹å®ã®ãŠã€ã«ã¹ãåµå·æ²»çã®ã¢ãã«ã§ãçç©åŠç掻æ§ã瀺ããŠããŸããããã«ãèšåºãŸãã¯åèšåºéçºæ®µéã«ããããŸããŸãªç ç©¶ããã°ã©ã ããããŸããKaryopharm Therapeutics Inc. 㯠2008 幎ã«èšç«ãããããµãã¥ãŒã»ããå·ãã¥ãŒãã³ã«æ¬ç€Ÿã眮ããŠããŸãã